Literature DB >> 1200844

Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine.

C W Potter, R Jennings, C McLaren, A Clarke.   

Abstract

A group of 23 student volunteers were each inoculated intranasally with 400 IU of inactivated, freeze-dried A/England/42/72 vaccine. Only one volunteer showed a four-fold rise in serum HI antibody following immunization, and the mean increase in serum HI antibody (gmt) for all volunteers did not increase two-fold. Thirteen of the volunteers developed detectable levels of nasal wash neutralizing antibody after immunization; local antibody was most commonly found in volunteers who produced a detectable but less than four-fold fise in serum antibody titre, and who produced nasal washings with relatively high concentrations of protein and secretory IgA. Four weeks after immunization, the vaccinees and a matched group of control subjects were inoculated with attenuated A/England/42/72 (MRC-7) virus. Evidence of infection was found in 14 of 23 (61 per cent) of control subjects and in seven of 23 (30 per cent) of immunized volunteers. This result showed a significant protection (P = 0.04) against challenge virus infection for volunteers given intranasal vaccine.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1200844      PMCID: PMC7102198          DOI: 10.1007/bf01317429

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  22 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

2.  Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic.

Authors:  G MEIKLEJOHN; C H KEMPE; W G THALMAN; E H LENNETTE
Journal:  Am J Hyg       Date:  1952-01

3.  Influenza immunization: field trial on a university campus.

Authors:  R H Waldman; W J Coggins
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

4.  Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route.

Authors:  J C Perkins; D N Tucker; H L Knope; R P Wenzel; R B Hornick; A Z Kapikian; R M Chanock
Journal:  Am J Epidemiol       Date:  1969-10       Impact factor: 4.897

5.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

6.  The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant.

Authors:  W Haigh; R W Howell
Journal:  J Soc Occup Med       Date:  1973-10

7.  Revised (1972-1973) bivalent influenza vaccine. Serum and nasal antibody responses to parenteral vaccination.

Authors:  R P Wenzel; J O Hendley; M A Sande; J M Gwaltney
Journal:  JAMA       Date:  1973-10-22       Impact factor: 56.272

8.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

9.  Reactions to an influenza virus vaccine in infants and children.

Authors:  J J QUILLIGAN; T FRANCIS; E MINUSE
Journal:  Am J Dis Child       Date:  1949-09

10.  The production of neutralizing activity in serum and nasal secretion following immunization with influenza B virus.

Authors:  J C Downie; C H Stuart-Harris
Journal:  J Hyg (Lond)       Date:  1970-06
View more
  5 in total

1.  Assessment of vaccine efficacy by challenge studies in man.

Authors:  D A Tyrrell
Journal:  Postgrad Med J       Date:  1976-06       Impact factor: 2.401

2.  Sequential infection or immunization of ferrets with a series of influenza A (H3N2) strains (report to the Medical Research Council's Sub-Committee on influenza Vaccines (CDVIP/IV)).

Authors:  C W Potter; R Jennings; M J Ali; J M Wood; U Dunleavy; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

3.  The hamster as an experimental animal for the study of influenza. I. The role of antibody in protection.

Authors:  R Jennings; M D Denton; C W Potter
Journal:  Med Microbiol Immunol       Date:  1976-12-01       Impact factor: 3.402

4.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

5.  Antigenicity in hamsters of inactivated vaccines prepared from recombinant influenza viruses.

Authors:  M Hamzawi; R Jennings; C W Potter
Journal:  J Hyg (Lond)       Date:  1981-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.